Physicians' Academy for Cardiovascular Education
Results from the EMPEROR-Reduced trial showed that SGLT2 inhibitor empagliflozin significantly reduced the risk of CV death or hospitalization for heart failure in HFrEF patients with or without diabetes.
The FDA has accepted the new drug application for vericiguat for priority review. The sGC stimulator vericiguat is under development for the treatment of patients with chronic HF with ejection fraction <45%.
Prof. De Boer discusses a recent paper in JAMA Cardiol on cardiac abnormalities detected by cardiovascular MRI in 100 patients who had proven COVID-19 around 2 months ago.
In HFrEF patients from the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin was similarly efficacious and safe in those receiving ARNI treatment and those not receiving ARNI treatment.
Cardiovascular MRI revealed cardiac involvement in 78% of patients and ongoing myocardial inflammation in 60% of patients in an unselected cohort of 100 patients who recently recovered from COVID-19.
Results from a meta-analysis showed that higher chocolate consumption (>1 time per week or >3.5 times per month) may be beneficial for CAD risk reduction compared to no consumption or <1 time per week.
The ACC Solution Set Oversight Committee has published a report with a decision pathway on how to manage bleedings in patients who used non-vitamin K oral anticoagulants (NOACs).
The SGLT2 inhibitor dapagliflozin reduced the primary endpoint and all secondary endpoints in the phase 3 DAPA-CKD trial, that enrolled CKD patients with and without T2DM.
Although incidence of recognized and unrecognized MI is higher in men, proportion of unrecognized MI is greater in women when compared to men. Yldau van der Ende presents the design and findings of her study.
Two heart failure specialists from Glasgow, UK discuss a patient case to demonstrate that it can be difficult to diagnose HFpEF. They present tools that can help in the process of diagnosing HFpEF.
Elevated Lp(a) levels were associated with greater risk of MACE in optimally treated patients with high-risk vascular disease when hsCRP levels ≥2 mg/L, but not in those with hsCRP levels <2 mg/L.
This expanded analysis of the CABANA trial showed that catheter ablation reduced symptomatic and asymptomatic AF recurrence and AF burden as compared to drug therapy over a 5-year follow-up period.
